Data Insights

Bexmarilimab by Faron Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Myelodysplastic Syndrome

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Anaplastic Thyroid Cancer: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Anaplastic Thyroid Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Anaplastic Thyroid Cancer

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Extrahepatic Bile Duct Cancer: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Extrahepatic Bile Duct Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Extrahepatic Bile Duct Cancer

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Pancreatic Ductal Adenocarcinoma

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Gallbladder Cancer: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Gallbladder Cancer

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Gastric Cancer: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Gastric Cancer

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Metastatic Uveal Melanoma: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Metastatic Uveal Melanoma

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Metastatic Ovarian Cancer: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Metastatic Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Metastatic Ovarian Cancer

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Metastatic Colorectal Cancer

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Metastatic Melanoma: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Metastatic Melanoma

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Metastatic Breast Cancer: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Metastatic Breast Cancer

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Refractory Acute Myeloid Leukemia

Data Insights

Bexmarilimab by Faron Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Relapsed Acute Myeloid Leukemia